BACKGROUND: Specific mutations leading to the development of various histological grades of intraductal papillary mucinous neoplasm (IPMN) have been partially characterized. METHODS: Analysis of 323 oncogenic mutations in 22 tumor-related genes was conducted, using a chip-based matrix-assisted laser desorption time-of-flight mass spectrometer of DNA extracted from microdissected cells of low-grade (n = 14), borderline (n = 6), and invasive IPMN (n = 7). Additional assays were performed on the DNA extracted from dyplastic cells found in the background of the adenocarcinoma. RESULTS: We identified 9 K-ras mutations (low grade, 2/14; borderline, 1/6; invasive, 6/7), 3 p53 mutations (low grade, 1/14; invasive 2/7), and 2 PIK3CA mutations (low grade, 1/14; invasive, 1/7). K-ras, p53, and PIK3CA mutations present in the invasive cancer were absent in the adjacent precursor cells in 50% of the cases. In one patient, K-ras mutation was present in the precursor lesion and absent in the adjacent invasive lesion. CONCLUSIONS: Of the 22 screened tumor-related genes, only K-ras, p53, and PIK3CA mutations were found in IPMN. K-ras mutations are more prevalent in invasive than premalignant IPMN. The variable coexistence of mutations in the invasive cancer and in the adjacent precursor cells may point to the heterogeneous nature of this tumor.
BACKGROUND: Specific mutations leading to the development of various histological grades of intraductal papillary mucinous neoplasm (IPMN) have been partially characterized. METHODS: Analysis of 323 oncogenic mutations in 22 tumor-related genes was conducted, using a chip-based matrix-assisted laser desorption time-of-flight mass spectrometer of DNA extracted from microdissected cells of low-grade (n = 14), borderline (n = 6), and invasive IPMN (n = 7). Additional assays were performed on the DNA extracted from dyplastic cells found in the background of the adenocarcinoma. RESULTS: We identified 9 K-ras mutations (low grade, 2/14; borderline, 1/6; invasive, 6/7), 3 p53 mutations (low grade, 1/14; invasive 2/7), and 2 PIK3CA mutations (low grade, 1/14; invasive, 1/7). K-ras, p53, and PIK3CA mutations present in the invasive cancer were absent in the adjacent precursor cells in 50% of the cases. In one patient, K-ras mutation was present in the precursor lesion and absent in the adjacent invasive lesion. CONCLUSIONS: Of the 22 screened tumor-related genes, only K-ras, p53, and PIK3CA mutations were found in IPMN. K-ras mutations are more prevalent in invasive than premalignant IPMN. The variable coexistence of mutations in the invasive cancer and in the adjacent precursor cells may point to the heterogeneous nature of this tumor.
Authors: Frank Schönleben; Wanglong Qiu; Karl C Bruckman; Nancy T Ciau; Xiaojun Li; Margaret H Lauerman; Harold Frucht; John A Chabot; John D Allendorf; Helen E Remotti; Gloria H Su Journal: Cancer Lett Date: 2006-11-09 Impact factor: 8.679
Authors: F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel Journal: Virchows Arch Date: 1994 Impact factor: 4.064
Authors: Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe Journal: Ann Surg Date: 2004-06 Impact factor: 12.969
Authors: K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram Journal: Int J Cancer Date: 1989-06-15 Impact factor: 7.396
Authors: Janel L Kopp; Claire L Dubois; David F Schaeffer; Atefeh Samani; Farnaz Taghizadeh; Robert W Cowan; Andrew D Rhim; Bangyan L Stiles; Mark Valasek; Maike Sander Journal: Gastroenterology Date: 2017-12-19 Impact factor: 22.682
Authors: Sujuan Yang; Sara P Y Che; Paul Kurywchak; Jena L Tavormina; Liv B Gansmo; Pedro Correa de Sampaio; Michael Tachezy; Maximilian Bockhorn; Florian Gebauer; Amanda R Haltom; Sonia A Melo; Valerie S LeBleu; Raghu Kalluri Journal: Cancer Biol Ther Date: 2017-01-25 Impact factor: 4.742
Authors: Dario Garcia-Carracedo; Andrew T Turk; Stuart A Fine; Nathan Akhavan; Benjamin C Tweel; Ramon Parsons; John A Chabot; John D Allendorf; Jeanine M Genkinger; Helen E Remotti; Gloria H Su Journal: Clin Cancer Res Date: 2013-10-16 Impact factor: 12.531
Authors: Eliana Amato; Marco Dal Molin; Andrea Mafficini; Jun Yu; Giuseppe Malleo; Borislav Rusev; Matteo Fassan; Davide Antonello; Yoshihiko Sadakari; Paola Castelli; Giuseppe Zamboni; Anirban Maitra; Roberto Salvia; Ralph H Hruban; Claudio Bassi; Paola Capelli; Rita T Lawlor; Michael Goggins; Aldo Scarpa Journal: J Pathol Date: 2014-07 Impact factor: 7.996